Clearmind Medicine Trial Continues After Safety Review
Ticker: CMND · Form: 6-K · Filed: Nov 24, 2025 · CIK: 1892500
Sentiment: bullish
Topics: clinical-trial, drug-development, healthcare
TL;DR
Clearmind's CMND-100 trial gets green light from safety board, good news for alcohol disorder treatment.
AI Summary
Clearmind Medicine Inc. announced on November 24, 2025, that its Data and Safety Monitoring Board (DSMB) unanimously approved the continuation of its Phase I/IIa clinical trial for CMND-100. This decision follows a positive interim safety review of the trial, which is investigating the potential of CMND-100 in treating alcohol use disorder.
Why It Matters
The positive safety review allows Clearmind Medicine to proceed with its clinical trial for CMND-100, a potential treatment for alcohol use disorder, bringing it closer to potential market approval.
Risk Assessment
Risk Level: medium — Clinical trial progress is a positive step, but the drug is still in early-stage development and faces significant regulatory and market hurdles.
Key Players & Entities
- Clearmind Medicine Inc. (company) — Registrant
- CMND-100 (drug) — Investigational drug for alcohol use disorder
- November 24, 2025 (date) — Date of press release and filing
- Data and Safety Monitoring Board (organization) — Oversight body for the clinical trial
FAQ
What is the primary purpose of the CMND-100 clinical trial?
The trial is investigating the potential of CMND-100 in treating alcohol use disorder.
What was the outcome of the interim safety review?
The Data and Safety Monitoring Board unanimously approved the continuation of the Phase I/IIa clinical trial following a positive interim safety review.
What is the filing form and date?
This is a Form 6-K filed on November 24, 2025.
What is Clearmind Medicine Inc.'s principal executive office address?
The address is 101 – 1220 West 6th Avenue, Vancouver, British Columbia.
What is the standard industrial classification for Clearmind Medicine Inc.?
The SIC code is 2834, Pharmaceutical Preparations.
Filing Stats: 286 words · 1 min read · ~1 pages · Grade level 13.7 · Accepted 2025-11-24 16:01:04
Filing Documents
- ea026694201-6k_clearmind.htm (6-K) — 11KB
- ea026694201ex99-1_clearmind.htm (EX-99.1) — 13KB
- ex99-1_001.jpg (GRAPHIC) — 2KB
- 0001213900-25-114124.txt ( ) — 28KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Clearmind Medicine, Inc. (Registrant) Date: November 24, 2025 By: /s/ Adi Zuloff-Shani Name: Adi Zuloff-Shani Title: Chief Executive Officer 3